For an 84‑year‑old woman with a four‑week history of rhinorrhea and white nasal discharge, is mometasone furoate (intranasal corticosteroid) administered twice daily (BID)?

Mometasone Furoate Dosing for Rhinosinusitis

For an 84-year-old woman with a four-week history of rhinorrhea and white nasal discharge, mometasone furoate should be administered as 2 sprays per nostril once daily (not twice daily) for initial treatment, though twice-daily dosing (2 sprays per nostril BID) can be used for more severe or refractory symptoms.

FDA-Approved Dosing

According to the FDA drug label, mometasone furoate nasal spray is approved for adults (≥12 years) at 2 sprays per nostril once daily 1. The standard adult dosing is:

• Initial dose: 2 sprays (100 mcg) per nostril once daily (total 200 mcg/day)
• For more severe symptoms: 2 sprays per nostril twice daily can be used (total 400 mcg/day)

Clinical Context and Evidence

Once Daily vs Twice Daily Dosing

The evidence shows both regimens are effective, but the choice depends on symptom severity:

Once-daily dosing (200 mcg total):

• FDA-approved standard dose 2
• Effective for allergic rhinitis and chronic rhinosinusitis 3
• Recent evidence shows no difference in efficacy between morning and evening administration 4, so timing can be based on patient preference
• Better for adherence in elderly patients

Twice-daily dosing (400 mcg total):

• More effective for acute rhinosinusitis - MFNS 200 mcg BID was significantly superior to placebo and amoxicillin in reducing symptoms 5
• Used in nasal polyposis treatment 6, 7
• Studies in chronic rhinosinusitis show various regimens including BID dosing 3
• Both 200 mcg BID and 400 mcg BID showed similar efficacy as adjunctive therapy 8

For This Specific Patient

Given the four-week duration (suggesting chronic rather than acute process) and white nasal discharge (not purulent), this presentation is consistent with:

1. Chronic rhinosinusitis without nasal polyps - where intranasal corticosteroids are first-line 3
2. Non-allergic rhinitis - where intranasal corticosteroids are effective 9

Start with once-daily dosing (2 sprays per nostril once daily) because:

• It's the FDA-approved standard dose
• Adequate for chronic rhinosinusitis symptoms 3
• Better adherence in an 84-year-old patient
• Lower systemic exposure (important in elderly)

Escalate to twice-daily dosing if:

• No improvement after 1-2 weeks
• Symptoms are severe or significantly impact quality of life
• Nasal polyps are identified on examination

Treatment Duration and Monitoring

• Initial trial: 4 weeks minimum 3
• Reassess at 1 week: If no improvement, consider increasing to BID or investigating other causes 9
• Long-term use: Safe for extended periods in elderly patients when needed 3
• Monitor for: Epistaxis (most common side effect), nasal irritation, and septal erosions 9

Important Safety Considerations in Elderly Patients

• Direct spray away from nasal septum to minimize epistaxis risk 9
• Examine nasal septum periodically for mucosal erosions 9
• No significant systemic effects at recommended doses, including no HPA axis suppression 8
• Well-tolerated with adverse event rates similar to placebo 5, 8

Clinical Algorithm

1. Start: Mometasone 2 sprays per nostril once daily
2. Week 1: Assess response
   • Good response → Continue once daily
   • Poor response → Increase to 2 sprays per nostril BID
3. Week 4: Reassess
   • Improved → Continue at effective dose
   • No improvement → Consider alternative diagnosis or add adjunctive therapy

The key distinction is that BID dosing is not the standard starting regimen but rather an escalation strategy for inadequate response or more severe disease.